Conjugated Estrogens
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Conjugated Estrogens: Migraine disorder
One-Sentence Summary
Conjugated estrogens are a hormone therapy marketed in Canada under several Premarin and Duavive products. The TxGNN model predicts they may be relevant for migraine disorder, but no clinical trials and no publication that tests conjugated estrogens in migraine are available, so the evidence level is L5 (model prediction only).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 0.9977 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 6 of 6) |
| Number of DINs | 6 (marketed: 6) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for conjugated estrogens are not available in the data compiled for this report. Based on general knowledge, they are a mixture of estrogens that act on estrogen receptors.
Menstrual and perimenopausal migraine is linked to fluctuations in estrogen levels, so stabilising estrogen exposure could in theory change migraine frequency. The clinical literature, however, shows inconsistent effects. Oral conjugated estrogens and cyclic regimens have worsened migraine in some postmenopausal women, while transdermal, continuous regimens tend to be better tolerated. The effect therefore depends on formulation and regimen. Migraine with aura also carries a higher risk of ischaemic stroke, and estrogen adds to that concern.
The model score reflects an association, not proof of benefit. The retrieved publications discuss hormones and migraine in general and do not test conjugated estrogens as a migraine treatment.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29521155 | 2018 | Review | Climacteric | Hormonal fluctuations, especially around the menopausal transition, are an important migraine trigger; effects vary by migraine type |
| 11306204 | 2001 | Cohort | Maturitas | Evaluated how hormone replacement therapy influences primary headaches in postmenopausal women |
| 12390622 | 2002 | Cohort | Headache | Compared three oral hormone replacement regimens and their effect on migraine course in postmenopausal women |
| 8309263 | 1994 | Review | Mayo Clinic Proceedings | Compared transdermal and oral estrogen therapy across groups of women; not specific to migraine |
| 14195735 | 1964 | Case series | Medizinische Klinik | Treatment of climacteric disorders with conjugated estrogens; not about migraine |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02043440 | PREMARIN VAGINAL CREAM | Not specified | Not specified |
| 02414678 | PREMARIN | Not specified | Not specified |
| 02414694 | PREMARIN | Not specified | Not specified |
| 02043386 | PREMARIN INTRAVENOUS | Not specified | Not specified |
| 02414686 | PREMARIN | Not specified | Not specified |
At least one more licence (DUAVIVE, DIN 02432854) is also valid. All 6 licences are currently valid.
Safety Considerations
- Drug Interactions: 100 interactions were found in the interaction screening. Examples rated Moderate include acarbose, hydrocortisone, dexamethasone, betamethasone, budesonide, triamcinolone, clarithromycin, aprepitant, clotrimazole and several antidiabetic drugs (e.g. alogliptin, canagliflozin, dapagliflozin, empagliflozin, dulaglutide, chlorpropamide). Cimetidine is rated Minor.
- Thrombotic and stroke risk: Estrogens raise thrombotic risk, and migraine with aura already carries a higher ischaemic stroke risk. This is a key concern for any migraine use.
Please refer to the package insert for full warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on the model alone (evidence level L5). No study tests conjugated estrogens in migraine, the published hormone-and-migraine data are inconsistent in direction, and the stroke and thrombotic risks are a real safety concern.
To proceed, the following is needed:
- Controlled studies of conjugated estrogens, or specific regimens, in migraine, separating migraine with and without aura
- Detailed mechanism of action data
- Package insert warnings and contraindications from Health Canada
- A stroke and thrombosis risk assessment for migraine populations
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.